Phosphodiesterases (PDEs) are a family of enzymes (PDE1 through PDE11) that degrade cyclic nucleotides—cAMP and cGMP—key second messengers in immune cell function. Elevated PDE activity within tumors and infiltrating immune cells can suppress T cell proliferation, skew macrophages toward immunosuppressive phenotypes, and impair antigen-presenting cell maturation. For example, PDE4 inhibition has been shown to restore T cell responsiveness and reduce regulatory T cell-mediated suppression. Likewise, PDE5 modulation can shift myeloid-derived suppressor cells (MDSCs) toward a less suppressive state.
Understanding PDE enzyme kinetics and modulator effects is therefore critical to immuno-oncology research and drug discovery. Creative Biolabs offers a robust PDE assay platform designed to quantitatively assess isoform-specific PDE activity, inhibitor potency, and downstream immunological effects, supporting efforts to restore immune function in cancer target validation and lead optimization studies.
We provide carefully designed assay formats to support diverse research goals, emphasizing relevance to tumor immunity:
Detection of PDE enzymatic cleavage using fluorescent analogs of cAMP/cGMP with high dynamic range and speed.
Gold-standard sensitivity measurement using [³H]-labeled cyclic nucleotides, ideal for low-abundance isoform profiling.
Tumor-immune co-culture systems using cAMP/cGMP reporters to monitor intracellular second-messenger changes following treatment.
Assess activity of PDE1–PDE11, with a focus on immune-relevant isoforms like PDE4 and PDE7 in T cells, and PDE5 in MDSCs.
Direct measurement of cyclic nucleotide levels in cell lysates or supernatants after genetic or pharmacological perturbation.
Automated screening workflows in 96- or 384-well format for dose-response curves, SAR campaigns, and lead validation pipelines.
Each assay is optimized for sensitivity (signal-to-background >10) and reproducibility (Z' >0.75), and can be adapted to both purified enzymes and cell-based models.
A1: Primarily PDE4 (cAMP-specific) in T cells, PDE5 (cGMP-specific) in MDSCs and macrophages, and PDE7 associated with Treg function.
A2: Yes. Our protocols support tumor-immune cocultures and primary immune cell assays with modular formats.
A3: We can integrate readouts such as cytokine release (e.g. IFN‑γ, IL‑2), activation marker expression, or proliferation assays.
A4: Yes. We accommodate compound libraries, pre-clinical candidates, and SAR experiments—with dose–response, IC₅₀, and pathway readouts.
A5: Fluorescent formats detect nanomolar substrate conversion, radiometric assays provide sub-picomolar resolution, ensuring versatility.
Creative Biolabs combines enzymology, immunology, and drug discovery expertise to deliver PDE profiling services tailored for oncology research. Whether mapping enzyme kinetics or screening immunomodulatory compounds, we provide help from experimental design through data interpretation.